Amunix Pharmaceuticals, Inc.
http://www.amunix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amunix Pharmaceuticals, Inc.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Sanofi Cements Artificial Intelligence Ambitions With OpenAI and Formation Pact
The French drugmaker’s aim is to become the first pharma company powered by artificial intelligence at scale, and the collaborations keep coming.
Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D
CEO Paul Hudson says that the French major will continue to progress early-stage cancer projects despite jettisoning some oncology programs in favor of reallocating much of its research budget to immunology.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Index Ventures
- Versartis Inc.
- Diartis Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice